

HCV testing in NSP (Needle and Syringe Provision) Community Pharmacies Pilot (Phase 2)

Report and Findings

September 2019

Authors

Dr Suman Verma, Pharmacy Testing Project Lead, Co-chair LJWG, Hepatology Consultant, Chelsea and Westminster Hospital Dr Emily Phipps, Public Health Speciality Registrar, Public Health England Dee Cunniffe, LJWG Policy Lead Dr Karthik Paranthaman, Consultant Epidemiologist, Field Service, Public Health England

This project was funded by MSD and Cephied in the UK under a Joint Working Agreement with the London Joint Working Group on Substance Use and Hepatitis C.

About LJWG

The London Joint Working Group on Substance Use and Hepatitis C (LJWG) is a group of expert clinicians and patient advocacy and voluntary sector leads, working in collaboration with a wide group of stakeholders with the common goal of implementing an integrated plan to drive improvements in the prevention, diagnosis, treatment and outcomes of hepatitis C in people who use drugs, and reduce the spread of the virus.

www.ljwg.org.uk

Contents

Executive summary	4
Background	6
Aims	7
Methods	7
Results	10
Discussion	17
Recommendations	20
References	21
Acknowledgements	22

Executive summary

Hepatitis C (HCV) is a blood borne virus that affects the liver and is predominately transmitted by contact with infected blood. In the UK, those at highest risk of contracting HCV are people who inject drugs (PWID), with national data demonstrating PWID account for over 90% of all HCV infections.

Since 2014, direct-acting, all oral antiviral treatments have revolutionized the treatment of HCV as well as mitigating complications such as liver failure, liver cancer and the need for liver transplantation. Direct-acting antivirals (DAAs) are effective in curing the infection in more than 90% of those infected with HCV of all genotypes, thus making the HCV elimination targets of the World Health Organisation (WHO) by 2030 and NHS England by 2025 achievable.

Despite this, diagnosis and treatment rates in HCV positive people who are actively injecting remain low. This vulnerable group faces many barriers to access existing services and need more accessible testing and treatment pathways given their high risks of HCV transmission and acquisition. The LJWG's phase 1 pharmacy pilot offered HCV antibody testing to PWIDs accessing needle and syringe programmes (NSPs) at specific community pharmacies and provided pathways to secondary care for treatment.

The LJWG's pharmacy testing pilot, phase 2, builds on learning from phase 1 in order to increase testing and treatment for those most at risk of HCV acquisition and transmission. Phase 2 provides point of care capillary blood testing for HCV RNA to PWIDs accessing NSPs from community pharmacies in London, whereas phase 1 tests provided on-the-spot HCV antibody testing. This change enables those with chronic HCV infection to be identified directly in the pharmacies. Both pilots aimed to ensure transition to treatment with pathways from NSP community pharmacies to tertiary treatment centres.

Six pharmacies providing NSPs across London took part in the phase 2 pilot between April 2018 and March 2019. Key findings were:

- Of the 308 patients offered HCV testing across all sites, 57% accepted (n=176).
- 38% (n = 66) tested positive for HCV, of whom 21% completed treatment (n=14).

- 29% (n=51) of those tested did not know that interferon-free treatment was available.
- 78% (n=137) of those tested would prefer to receive HCV treatment in their community pharmacy, followed by 9% (n=16) reporting they would prefer to receive treatment from a GP practice.
- Over three-quarters (78%) of people reported having previously been tested for HCV, and 41% said they had been tested within the last year.
- 75% (n=132) of service users said they would recommend the pharmacy testing service to a friend.

Following on from the success of the phase 1 pilot conducted in 2017-18, this report confirms the feasibility and value of offering point of care HCV diagnosis to PWIDs attending community pharmacies for needle exchange services. This report provides valuable insights for future HCV testing programmes in pharmacies and recommends a broader roll-out.

Background

Hepatitis C is a blood borne virus that causes chronic liver disease. It is estimated that around 113,000 people live with chronic HCV infection in England. People who inject drugs carry the greatest burden of infection, with around half of all PWIDs in England and Wales estimated to have been infected with HCV (1).

The advent of direct-acting antivirals has revolutionised treatment of HCV, achieving virological cure or sustained virological response (SVR) in over 90% of patients. In the last few years, NHS England has expanded access to DAA treatment across the country, with patients being prioritised through Operational Delivery Networks (ODNs). To achieve elimination of HCV as a major public health threat by 2030, it is critical that treatment uptake is maximised in actively injecting PWIDs, the group most affected by this infection with the highest acquisition and transmission rates (1; 2).

Previous studies have demonstrated that the delivery of HCV testing through pharmacies is an effective method of engaging with this cohort (3; 4; 5). A recent phase 1 pilot by the LJWG involving point of care testing using oral fluid test (OFT) for HCV antibody had demonstrable success in increasing testing uptake by PWIDs accessing needle and syringe programmes (NSPs) through community pharmacies in London (6). However, the phase 1 pilot had considerable loss to follow-up after pharmacy testing, as further investigation of RNA status through secondary care was required to confirm the diagnosis before treatment could be initiated in secondary care (6).

Drawing upon learning from the phase 1 pilot, a phase 2 pilot was designed to evaluate chronic HCV diagnosis in this population using capilliary blood testing for HCV RNA instead of OFT used in phase 1. This was the first time worldwide that capilliary blood testing for HCV RNA was employed in a non-clinical setting. Enhanced peer support was also implemented to determine whether engagement with treatment services could be increased, and drop-out rates reduced.

Aims

The aim of the phase 2 pilot was to reduce the impact of hepatitis C in actively injecting PWIDs, by facilitating access to immediate chronic HCV diagnosis in NSP community pharmacies using point of care testing HCV RNA capillary blood test and ensuring enhanced support for transition into treatment for this vulnerable population.

The objectives of the analysis in this report are to:

- Ascertain the prevalence of hepatitis C among the tested pilot cohort.
- Determine uptake and loss to follow-up at each point in the care cascade.
- Explore whether the service delivery model was acceptable to service users and pharmacy staff.
- Identify barriers and facilitators to engagement with services.
- Compare uptake and engagement with the phase 1 pilot to determine which elements of the service models are most effective at improving uptake.

Methods

The testing model in phase 2 was similar to phase 1, with the major difference being the use of Cepheid capillary blood test for HCV RNA detection. This was the first study worldwide to use the Cephied test in a non-clinical environment. Further details of the methodology can be found in the phase 1 report (6).

Pharmacies were invited to take part in the phase 2 pilot on recommendation to the LJWG by the Local Pharmaceutical Committee and needle exchange commissioners. Pharmacy staff were trained in the methods of the pilot by the LJWG (see phase 1 report) and provided with a Standard Operating Procedure (SOP). Cepheid undertook a joint training session on use of the point of care testing machine for representatives from each pharmacy at an evening event. Company technicians made regular site visits and were contactable by telephone in case of any queries. The care pathway for phase 2 is summarised in Figure 1.

Quantitative data on service users' testing uptake and onward referral to secondary care was captured using a handwritten or electronic form, depending on pharmacy preference (appendix


2). A unique ID was generated for each patient and used to track outcome data in terms of attendance of secondary care appointments, uptake and completion of treatment.

Feedback questionnaires for pharmacy staff and service users were designed and tested prior to implementation (see appendix 2). For service users, the survey was completed over the counter at the point of care, and staff feedback was captured at a time convenient for them to complete the survey.

Following a request from the LJWG, the Public Health England (PHE) Field Service agreed to assist with analysis of the data and report writing. No patient-identifiable information was provided to or stored by PHE. Data was analysed in accordance with PHE policies on information governance and record keeping. All files will be processed by Field Services South East and London (FS SEaL) in accordance with PHE record retention policies.

Quantitative analysis was undertaken using STATA 15. Key themes from the qualitative survey were explored to gain further insight into the experiences of patients as well as pharmacy staff.

This pilot evaluated extending access to a standard hepatitis C testing practice that is already in use within other areas of the NHS. Care professionals and the service users themselves determined the choice of care accessed in line with professional guidance and user preference. The pilot was therefore deemed a service evaluation and so a Research Ethics Committee review was not required. All staff taking part in the pilot adhered to their respective professional codes of ethics in their conduct and actions.





Results

Pharmacy engagement

Six pharmacies took part in the phase 2 pilot between April 2018 and March 2019. The period of activity for each pilot site ranged between 15 and 329 days, with a median of 173 days.

The total number of eligible population attending these six pharmacies could not be calculated as individuals could register at more than one pharmacy and did not need to provide their unique identifiable details such as date of birth or name to obtain NSP pharmacy services. Pilot sites reported that 308 patients were offered testing, of which 176 accepted the capillary test. Assuming that the data are reliable, this would give a test acceptance rate of 57% (95% confidence interval: 51.4% - 62.7%). Among those tested and reporting the reason for attending the pharmacy, 83% reported needle exchange and 17% reported both supervised consumption and needle exchange as the primary reason for attending the pharmacy.


The number of tests performed by each site during the total pilot period varied between 9 and 100 (Table 1 and Figure 2). Taking into account the range in activity periods between sites, the average number of tests per week ranged between 0.6 tests to 4.2 tests per week.

Further data presented relate to the 176 patients who accepted the offer of testing.

Table 1. Activity period and number of tests performed by pharmacies, LJWG pilot phase 2, 2018-19

			Activity	Number of	Average
Pharmacy	First Test	Last Test	Period	tests	tests per
			(in days)	conducted (%)	week
Portmans Pharmacy	25/04/2018	20/03/2019	329	100 (57%)	2.13
Junction Pharmacy	10/07/2018	18/12/2018	161	23 (13%)	1
St Georges Pharmacy	16/05/2018	16/11/2018	184	20 (11%)	0.76
Market Chemists	19/05/2018	22/11/2018	187	16(9%)	0.6
Hills Pharmacy	31/05/2018	15/06/2018	15	9 (5%)	4.2
Mintons Chemist	14/09/2018	24/10/2018	40	8 (5%)	1.4
Total				176 (100%)	

Figure 2. Activity period and number of tests performed by pharmacies, LJWG pilot phase 2, 2018-19



Demographic factors

The mean age of those accepting testing was 42 years (range 22 to 61 years) and the majority (82%) were male. The age and gender distribution of participants is summarised in the population pyramid in Figure 3.




Figure 3. Age-sex pyramid of those accepting HCV testing in pharmacies, LJWG pilot phase 2, 2018-19

Most participants described their ethnicity as White British (n=122; 69%). Other ethnic groups, including Asian, Caribbean and mixed backgrounds, constituted almost 19% (n=33), and the remaining 12% (n=21) were of other White ethnic background.

Number tested

Previous testing and treatment

Over three-quarters (78%; n=135) reported having previously been tested for hepatitis C. Among those reporting previous testing, 41% (n= 55) reported being tested within the last year and 56% (n=76) reported being tested more than one year ago.

As shown in Table 2 below, compared to those tested within the previous year, HCV RNA positivity was higher in those who did not report being tested in the previous year, although this was not statistically significant (p>0.05).

T I I A A III					
Table 2. Capillar	y test result b	y self-reported	previous test date,	LJWG pilot	phase 2, 2018-19

Self-reported previous test date	Number of patients	Capillary test result			
		Positive	Negative		
Less than one year ago	55	18 (33%)	37 (67%)		
More than one year ago	78	30 (38%)	48 (62%)		
Not known	43	18 (42%)	25 (58%)		
Total	176	66	110		

Table 3 shows self-reported previous test result compared with capillary test results. Of note, 19% of those who reported a previous negative result had a positive result, whereas 63% of those who reported a previous positive result continued to be positive. HCV RNA positivity with the capillary test was 44% among those who did not know their previous test result.

Table 3. Self-reported previous test result compared to capillary test result, LJWG pilot phase 2,2018-19

Self-reported previous test result	Number of	Capillary test result			
	patients	Negative	Positive		
Negative	84	68 (81%)	16 (19%)		
Not known	41	23 (56%)	18 (44%)		
Positive	51	19 (37%)	32 (63%)		
Total	176	110	66		

Of the 22 participants who reported having previously received treatment for HCV, 15 reported having previously completed HCV anti-viral treatment (3 were HCV RNA capillary test positive) and the remaining five reported either partial or no treatment previously (2 were HCV RNA capillary test positive).

Viral load

The capillary blood test kit reported viral load for all positive HCV results. Five participants (6.58%) had a HCV viral load of 100 IU/ml or less in this cohort. The median viral load was 468,500 IU/ml (Q1: 62300 IU/ml and Q3: 2,210,000 IU/ml). All participants with a positive test, regardless of viral load, were referred to secondary care.

Use of vouchers and peer support

Among the 66 patients with HCV RNA positive results, contingency management vouchers for receiving their result were issued in pharmacies to 64 patients. Peer support was offered to 24 patients, of which nine who accepted attended secondary care. Of the 36 not offered peer support, 12 attended secondary care.

Treatment outcome


Among 66 patients, 60 patients were referred to secondary care for further investigation and treatment, of which 21 attended outpatient appointments. Among six patients who declined referral, three had a HCV viral load of <100 IU/ml and the rest had viral load of <300,000 IU/ml.

On genotyping, the majority were genotype 1a (10 patients) or genotype 3 (9 patients). None of the participants were HIV or HBV positive.

18 patients started treatment, of which 14 completed treatment and the other four discontinued treatment before completion. Among those who completed treatment, four were confirmed to have SVR at 12 weeks, eight were pending and two did not attend their appointment.

Among the 21 patients seen in secondary care, four patients were diagnosed as having cirrhosis. Of these, two completed treatment, one did not attend their clinic appointment after four weeks of treatment and another did not attend for treatment initiation.

Figure 4. Care cascade, LJWG pilot phase 2, 2018-19



Comparison with Phase 1

Outcome data was compared between phase 1 and phase 2 pilots for attendance of secondary care services and treatment completion. The proportion of patients testing HCV positive in phase 2 was 37.5%. There was no significant difference between phase 1 and phase 2 with regard to attendance at secondary care services (p>0.05) and treatment completion (p>0.05).

Table 4. Comparison of LJWG pilot phases 1 and 2, 2018-19

	Eligible	Proportion positive	Attended	Number	Number
	tests	(95% CI)	secondary	started	completed
			care (%)	treatment	treatment
		47.8%			
Phase 1	178	HCV antibody	23 (27%)	16	2*
Fliase I		postive	23 (27 /0)		2
		(40%-55%)			
		37.5%			
Phase 2	176	HCV RNA postive	21 (32%)	18	14*
		(30.3-45.1%)			

* Numbers correct at the time of phase 1 and phase 2 report writing; likely to be an underestimate of actual numbers completing treatment

Service user feedback

Service users rated their HCV testing experience on a scale of 1 to 10, with 1 being "very poor" and 10 being "excellent". The mean rating was 9.3 (range 6 to 10). Three-quarters of service users reported that they would recommend the pharmacy testing service to a friend.

When asked where they would like to receive HCV treatment if found to be positive on testing, the majority (78%) reported they would like to receive it at the pharmacy, followed by 9% of service users preferring GP surgery for treatment. The remaining 13% of users were split between drug treatment service and hospital as preferred locations for accessing treatment. When asked if they were aware that current HCV treatment did not involve interferon injections and involved tablets only, 71% reported that they were aware and the rest reported not being aware.

Pharmacy feedback

All six pharmacies provided a feedback response on their experience of taking part in phase 2:

• Communication from the LJWG (1= very poor, 5= excellent) – mean 4.8

- Willingness of service users to participate (1= not willing to engage, 5= all willing to engage) – mean 3.3
- Ease of testing process (1= very difficult, 5= very easy) mean 4.5
- Ease of filling forms (1= very difficult, 5= very easy) mean 4.8
- Ease of referral process (1= very difficult, 5= very easy) mean 4.7
- Engagement of service users in having a conversation about testing/having the test (1= not engaged, 5= very engaged) – mean 3.75

Pharmacy staff reported that they had received generally good feedback from participants, appreciating that the service was quick, convenient and easy. The common reasons for declining testing reported by pharmacy staff was that the client stated they were busy, or had had the test done recently, or wanted to get it done the next time they attended the pharmacy. One pharmacist reported that test uptake was better if the pharmacy had developed a good relationship with the service user as part of opiate substitution therapy. Respondents suggested ways to improve uptake, including designing posters, leaflets, and working with other organisations to raise awareness (e.g. social services and other pharmacies).

Challenges reported by pharmacy staff included difficulties in taking blood, especially in cold weather. One pharmacy reported difficulties in working the testing machine.

Pharmacy staff requested confirmation of receipt of referral from secondary care services, as this was reported as currently variable. It was suggested that if pharmacy staff were informed of the clinic appointment date, they would be able to encourage and remind patients to keep their clinic appointment.

Discussion

Following on from the success of the phase 1 pilot conducted in 2017-18, this report confirms the feasibility and value of offering point of care HCV diagnosis to PWIDs attending community pharmacies for needle exchange services. Feedback from service users and pharmacy staff for HCV testing and referral service has been overwhelmingly positive. Pharmacies providing needle

exchange services for PWIDs are an important location to "diagnose the undiagnosed" HCV cases.

Engagement from pharmacy was suboptimal due to limitations in resources for the pilot, in terms of the number of pharmacies signed up to offer testing in phase 2, the activity period when the service was offered and the number of tests undertaken among the eligible population. Nevertheless, 176 service users were tested, of which 66 were diagnosed with HCV infection. Further work is needed to explore how best to improve the engagement of those pharmacies that performed less well in offering an HCV testing service.

The reasons for the substantial fall in secondary care attendance following referral are not clear. Only a third of patients who were referred went on to attend clinic appointment, suggesting barriers in accessing secondary care services. One of the positive findings is that the vast majority who attended clinic appointments in secondary care were able to start treatment with DAAs and over two-thirds completed treatment. Of note, over three-quarters of users stated pharmacies as their preferred location for accessing treatment if it were to be offered.

It is encouraging to note that most service users (78%) reported having been tested for hepatitis C previously, with over 30% of all service users being tested within the previous year. An important finding is that almost two-fifths of those who reported a previous negative result had a positive result, reaffirming the need for regular testing of this high-risk group regardless of previous test history. Additionally, self-reported positive previous test appears to be a useful marker for HCV infection, with almost two-thirds (63%) of those who reported a previous positive result confirmed as having HCV infection by capillary tests. Unsurprisingly, we found that positivity was higher in those who did not report being tested in the previous year although this was not statistically significant due to small sample size. This also demonstrated re-engagement of those previously known to have chronic HCV infection.

Contingency management vouchers were well-utilised in phase 2 and almost all patients diagnosed with HCV infection were offered and accepted this incentive. Although peer support was offered to some of those testing HCV RNA positive, more work needs to be done to identify why the offer and uptake was low. Peer support has been shown to be successful at engaging people using drug services in accessing treatment in secondary care (7), so perhaps an adapted model is needed in the pharmacy setting.

The prevalence of HCV in phase 2 among those tested was 37.5%, which, while lower than the phase 1 figure of 48%, needs to be interpreted with caution. The primary reason for this variation is that positivity was measured by HCV antibody alone in phase 1 thus identifying those with previous *exposure* to HCV who may not necessarily have chronic HCV infection. Whereas in phase 2 HCV RNA was used, providing a more reliable marker of chronic HCV infection. With regard to outcome data such as clinic attendance and completion of treatment, there were no substantial differences between phase 1 and 2, although the sample sizes were small in both phases to detect meaningful differences.

Analysis of the feedback from service users and pharmacy staff has provided further insights to inform wider implementation of this programme. It is important that relevant written materials including SOP and referral letters are developed and shared with pharmacies providing this service, and adequate training is provided to pharmacy staff on HCV, test counselling, use of testing equipment and the referral process. Secondary care providers should consider how best to acknowledge referral of new patients by community pharmacists if this is not routinely done. Almost 30% of patients were not aware that newer tablet treatments are available for HCV, suggesting scope for further development of resources to raise awareness, such as leaflets and posters, and holding engagement events.

There are several limitations to this study. First, while pharmacy staff received training on test counselling and use of the point of care machine, standardised practice between pilot sites cannot be guaranteed, and there may be some systematic differences in how the pilot was conducted at pharmacy level. Furthermore, differing levels of engagement of pharmacy staff could have had an impact on the number of people invited to take part in the pilot. Second, due to current service configuration and operational reasons, it was not possible to measure or estimate the overall population of PWIDs attending the six pharmacies who would have been eligible for testing in the phase 2 pilot. Third, data on previous testing and treatment was provided by service users and could not be verified for reliability. The use of free text and lack of data format requirements also led to poor quality information for certain variables (e.g. previous test date) and necessitated a degree of estimation to collapse into categories. Fourth, we were unable to adequately capture the reasons why two-thirds of those testing positive for HCV did not attend secondary care service for further assessment and treatment.

19

Recommendations

1. HCV testing and treatment is necessary for PWIDs actively injecting. 37.5% of those tested had chronic HCV infection, which is higher than that seen in the prison population. This confirms the importance of testing and treating this vulnerable population.

2. HCV testing should be rolled out in selected pharmacies across the country. The recent *Community Pharmacy Contractual Framework for 2019/20 to 2023/24* provides an exciting opportunity to expand hepatitis C testing for people accessing needle exchanges in community pharmacies (8). With £4 million announced to fund hepatitis C testing in this setting, this report, alongside the phase 1 report (6), has provided key insights to delivering testing in pharmacies. To avoid duplicating efforts and to ensure people who are at risk of infection or re-infection through injecting drug use are targeted effectively, the SOPs developed for this and the previous pilot have the potential to be utilised in developing a testing programme.

3. A campaign targeting actively injecting PWIDs is needed to increase awareness that treatment for HCV is now all oral tablets. This may increase the uptake of both testing and treatment in this at-risk population.

4. The Government should overcome legislative barriers to support the roll-out of hepatitis **C** treatment in pharmacies. When asked where they would prefer to be treated for hepatitis **C**, the majority of people already accessing a hepatitis **C** test at a community pharmacy in both phase 1 (84%) and phase 2 (78%) of the pilot said they would like treatment in the same setting. This, together with the significant drop-out at the secondary care attendance level, requires a more patient centred approach to HCV treatment delivery. The Department of Health and Social Care needs to overcome the legislative barrier preventing hepatitis **C** treatment from being dispensed in pharmacies so that those most at risk can more readily access medication.

References

1. Public Health England. Hepatitis C in England 2019. London: PHE, 2019.

2. World Health Organisation. WHO Global Health Sector strategy for viral hepatitis 2016-2021q. Geneva : WHO, 2016.

3. Radley A, Tait J, Dillon JF. DOT-C: a cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy. s.l. : International Journal of Drug Policy, 2017. pp. 126-136.

4. **Radley A, Melville K, Tait J, et al.** A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland. Frontline Gastroenterology, 2017. pp. 221-228.

5. Buchanan R, Hasan-Hicks P, et al. Integrating community pharmacy testing for hepatitis C with specialist care. s.l. : Clinical Pharmacist, 2016. p. Online.

6. Verma S, Leeman D. HCV testing in NSP (needle and syring provision) community pharmacies pilot (phase 1). London : London Joint Working Group on Substance Use and Hepatitis C, 2018.

7. **Stagg H, Surey J, et al.** *Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention.* s.l. : BMC Medicine, 2019.

8. **Department of Health & Social Care.** The Community Pharmacy Contractual Framework for 2019/20 to 2023/24: supporting delivery for the NHS Long Term Plan. 2019.

Acknowledgements

The LJWG Steering Committee

Dr Suman Verma, Consultant Hepatologist, Chelsea and Westminster Hospital Dr Emily Finch, Consultant Addictions Psychiatrist, South London and Maudsley Dr Kosh Agarwal, Consultant Hepatologist, Kings College Hospital Dr Ashwin Balabhadra, GP with Special Interest, Haringey Prof Ashley Brown, Consultant Hepatologist, St Mary's and Hammersmith Hospitals Janet Catt, Nurse Consultant, Kings College Hospital Viv Evans, Chief Executive, Adfam Rachel Halford, Chief Executive, The Hepatitis C Trust Dr Magdalena Harris, Qualitative Sociologist, London School of Hygiene and Tropical Medicine Sarah Hart, Senior Commissioner for Substance Misuse and Sexual Health, Public Health Haringey Prof William Rosenberg, University College London John Jolly, Chief Executive, Blenheim Sharon Daughter, Executive Director of Operations in London and the South, Humankind

With thanks to the following organisations

Blenheim Cadge Pharmacy, Haringey Caregrange Pharmacy, Chelsea and Westminster Central and North-West London NHS London Trust Cepheid CGL Drug and Alcohol Service Devon LPC Haringey Public Health Health Inclusion Team, Adult Community Health 3 Boroughs Team (GSTT) The Hepatitis C Trust Inclusion Health, Kings Health Partnership Kensington, Chelsea & Westminster LPC

Kensington, Chelsea & Westminster, Hammersmith and Fulham Local Pharmaceutical Committee Lambeth CCG Lambeth Public Health and Health Protection Lambeth, Southwark & Lewisham Local Pharmaceutical Committee Lorraine Hewitt House Drug and Alcohol Service, Lambeth (SLAM) Middlesex Local Pharmacy Committee Mintons Pharmacy Haringey MSD North Central London ODN PHE London: NENCL, SL and NWL Health Protection Teams PHE Field Service **Portmans Pharmacy Westminster** Public Health Department, Westminster, Hammersmith and Fulham, Kensington and Chelsea PHE National Infection Service **SLAM Pharmacy Needle Exchanges** South Thames (HepNet) ODN Southwark Public Health and Health Protection The Grove Drug and Alcohol Service BEH NHS Trust **Turning Point** West London ODN

With thanks to the following individuals

Gerald Alexander, Chair, Barnet, Enfield and Haringey Local Pharmaceutical Committee, The Middlesex Pharmaceutical Group of LPCs Dr Kosh Agarwal, Consultant Hepatologist, Kings College Hospital Alice Bonnissent, Cepheid Prof Ashley Brown, Consultant Hepatologist, St Mary's and Hammersmith Hospitals Nicola Ashton, Senior Commissioning Manager Public Health Department, Hammersmith and Fulham Dr Mary Cannon, Locum Consultant Hepatologist, King's College Hospital Gabriel Castillo, Sonar Informatics Iona Casley, Principle Consulting Janet Catt, Nurse Consultant, Kings College Hospital Jack Coleman, Hills Pharmacy

Mick Collins, Borough Lead, Lambeth Addictions Consortium, South London and Maudsley NHS Foundation Trust

Aisling Considine, Pharmacy Team Leader Liver & Private Patient Services, Kings College London

Archie Christian, Pathways Coordinator, The Hepatitis C Trust

Kar Man, Chung Hills Pharmacy

Jane Cox, Director, Principle Consulting

Will Davis, Team Manager, Barnet, Enfield and Haringey Mental Health NHS Trust

Gaynor Driscoll, Head of Commissioning, Adults, Public Health Department H&F, RBKC and WCC

Dr Ahmed Elsharkawy, Consultant Transplant Hepatologist University Hospitals Birmingham NHS Foundation Trust

Professor Kevin Fenton, Director, Health and Wellbeing, London Borough of Southwark

Dr Matthew Foxton, Consultant Hepatologist Chelsea and Westminster Hospital

John Gibbons, Groundswell

Dr Indrajit Ghosh, Specialty Doctor, Mortimer Market Centre, CNWL NHS FT

Sam Gokal, Mintons Pharmacy

Rachel Halford, Chief Executive, The Hepatitis C Trust

Lorna Harrison, Clinical Nurse Specialist, Hepatology, Imperial College

Sarah Hart, Senior Commissioner for Substance Misuse and Sexual Health, Public Health, Haringey

Sarah Hodgson, Hepatology Specialty Nurse, Kings College London

Mike Kelleher, Consultant Addictions Psychiatrist, Lorraine Hewitt House Lambeth

Chris Laker, Peer Support Lead, South East London, The Hepatitis C Trust

Michael Levitan, Chief Executive, Middlesex Pharmaceutical Group

Urte Macikene, Principle Consulting

Dr Sema Mandal, National Infection Service, PHE

Laura Manders, Portmans Pharmacy

Raj Matharu, Chief Executive, Lambeth, Southwark & Lewisham Local Pharmaceutical Committee

Serena McCabe, Clinical Services Manager (Substance Misuse), Barnet, Enfield and Haringey Mental Health NHS Trust

Martin McCusker, Lambeth Service User Council

Fred McGruer, Nurse Manager, Turning Point Miranda Mindlin, Consultant in Communicable Disease Control, PHE London Shiraz Mohamed, Market Chemists Caroline Nelson, Barnet, Enfield and Haringey Mental Health NHS Trust Kath Oakes, Viral Hepatitis Team Lead, Kings College London Michael O'Sullivan, Junction Pharmacy Akeem Ogunyemi, Commissioner, Sexual Health, Haringey Council Dr Karthik Paranthaman, Consultant Epidemiologist, Field Service, PHE Graham Parsons, Lead Pharmacist (Turning Point), Pharmacist Prescriber (Hammersmith & Fulham DAWS) Atul Patel, St Georges Pharmacy Southwark Bhaveen Patel, Junction Pharmacy Brixton Hemang Patel, Turning Point Jasumati Patel, Portmans Pharmacy Jayesh Patel, CEO Lambeth Southwark and Lewisham LPC **Tushar Patel**. Mintons Vikash Patel, Mintons Sharon Pedliham, Kensington and Chelsea Borough Manager Michele Roberts, Public Health, Hammersmith and Fulham Sarah Robinson, Head of Programmes, Health Protection, Public Health Southwark Prof William Rosenberg, University College London Ahmad Sadiqzai, Market Chemists Amit Shah, Superintendent Pharmacist, AR Chemist Rekha Shah, Chief Executive, Kensington Chelsea & Westminster LPC Sital Shah, Senior Clinical Pharmacist, Liver Services, Kings College Hospital Terry Shields, Needle Exchange Coordinator, South London and Maudsley NHS Foundation Trust Rhiannon Sheppard, Clinical Nurse Specialist, Hepatology, Chelsea and Westminster Hospital Dr Caroline Shulman, General Practitioner in Homeless and Inclusion Health, Kings Health Partnership Ruth Simmons, PHD Epidemiologist, PHE Lizzie Smith, HCV Programme Manager, STHepNet ODN Stuart Smith, Director of Community Services, The Hepatitis C Trust Mark Stone, Devon LPC Project Pharmacist

Julian Surey, Research Nurse, Institute of Global Health UCL Anar Tejani, Portmans Pharmacy Westminster Shailesh Thakrar, My Pharmacy Pritpal Thind, Director, Sonar Informatics Limited Simone Thorn Heathcock, Nurse Consultant in Health Protection, PHE London Dr Andy Ustianowski, Consultant in Infectious Diseases & Tropical Medicine, North Manchester General Hospital and Hon Senior Lecturer, School of Medical Sciences, University of Manchester Dr Marie Noelle Vieu, Public Health Consultant, Health Protection, Lambeth Council Nick Walker, Aurora Project, Lambeth Volunteer Manager

Appendix 1- HCV testing paperwork (Data collection form)

LONDON JOINT

WORKING GROUP ON SUBSTANCE USE

+ HEPATITIS C

Client Questionnaire									
1. Did you attend pharmacy for:									
Needle X 🗖 Supervised Consumption & Needle X 🗖 Other 🗖									
2. Do you attend a drug and alcohol service. Yes 🗆 No 🗖									
2. Were you aware of the Hepatitis C testing service before you came today?									
Yes No No If yes where did you hear about the testing service?									
3. If you require treatment where would you ideally receive this?									
Hospital 🗖 GP 🗖 Pharmacy 🗖 Drug Treatment Service 🗖									
Other 🗖 (Please Specify):									
4. How would you rate the test experience you received today?									
Very Poor 1 2 3 4 5 6 7 8 9 10 Excellent									
5. Would you recommend this test to a friend?									
Yes 🗆 No 🗖									
6. If No, why not?									
7. Are you aware current treatment does not involve interferon injections and is tablets only?									
Yes 🗆 No 🗖									

Pharmacy		GP Name and address							
					□ No ⁻	t registe	red w	ith a GP	
Date of test:									
Client Name:									
Date of Birth:									
Gender	Male 🗖	Ferr	nale						
Ethnic Origin:	White British Black British Black Other East Asian Other:			White Iri Black Afr Asian Bri Asian Otl	ican tish		Blac Sout Mixe	te Other k Caribbean th Asian ed ner not Say	
Contact Address:									
Post Code:									
Telephone No:									
Alternative No:					Conta Relati	act onship	:		
If we are unable t	o contact yo	u do ye	-	ive con our alte		•		Yes 🗖	No 🗖
Testing History									
Have you been teste Hepatitis C previous		Yes 🕻]	No 🗖	Do	on't kn	ow E		
Approximate Date	of last test:								
	Location:	GP □ Other		g/Alcoh	ol Servi	ce 🗖 Se	exual	Health Serv	/ice 🗖
	Results:	Posit	ive [egativ	e 🗖 No	ot kn	own 🗖	
Have you been	treated for		-					-	

Yes 🛛 🛛 No 🗖

Hepatitis C previously?

Don't know 🗖

Hepatitis C Screening Service

London Pharmacies

Can you remember	
where and when?	
Did you complete treatment	
and informed you were cured?	Dama
Pre-Test Check List	Done
Explained what GeneXpert process will entail	
Explained how and when results will be given and arrangements for follow- up for a positive RNA test, including referral	
Explained possible 3 month window period for re-testing if recently at risk	
Offered contingency management voucher of £5	
Explanation of the implications of a positive result	Done
They may have difficulty securing Life / Health Insurance as is common with many chronic (long term) illnesses	
Hepatitis C can lead to severe liver damage and an increased risk of cancer. However there is effective treatment available.	
They have received a copy of the hepatitis B and C information.	
Consent	
 I have had the GeneXpert explained to me and I consent to the test bein and anonymous information being used by the LJWG, the local health see Chelsea and Westminster Hospital. I consent to the specialist service at the hospital being given details of an RNA test results. If the test result is positive I am happy for my contact details to be share Hepatitis C Trust who can provide support to access treatment. If you would prefer not to do this please tick this box. □ I am happy for the test results to be shared with my GP if blood tests she have been diagnosed positive for a blood born virus – This is to ensure the can receive the best care possible if your test result is positive and the G of current medications. If you do not collect your GeneXpert results we will forward them to you you would prefer we don't do this please tick this box □ 	ervice and ny positive ed with The ow that I hat you iP is aware
Client Signature: Date:	

Test Results										
Hepatitis C RNA		🗖 Positi	ve	🗖 Nega	itive					
Unique identifier	Jnique identifier IU/ML									
If test declined why? Already tested 🗖 already HCV positive 🗖 Not interested 🗖 Addition information -										
Results Appointment					Done					
Information about Hepatitis C, on treatment available and give client a copy of 'Hep C Info' or 'Hep C Care booklet										
Advice on how to prevent passing H	epatitis C	to others								
Client referred on to appropriate loc treatment	cal service	for furth	er assessme	nt and						
Contingency Management Voucher	accepted	?								
If referred on please state where they have been referred to:										
Peer support offered:	Acc	epted 🗖	Decline	d 🗖						
Peer assigned:	Yes	D N	o 🗖							
Negative Results Checklist					Done					
Recommend re-test if at risk recentle										
Advise on prevention in future and give negative test information										
If they are at risk of Hepatitis B or HIV recommend testing and hepatitis B vaccination										
If they remain at risk from Hepatitis										
Declined Tests Checklist (fill in daily)	No inter	est	Already tes	ted	Other					

This document has been produced for the LJWG on Substance Use and Hepatitis C for use by pharmacies participating in the HCV testing pilots Phase 2.

This document has been adapted from a document provided by Graham Parsons from Turning Point and the Devon Local Pharmaceutical Committee. The LIWG would like to thank Graham and the Devon LPC for permission to adapt this paperwork for use within this pilot.

Appendix 2- Hospital referral form

Patient details								UID *		Refe date			
Surname:	Fir							ne(s):					
Address:													
Telephone:	NHS Number:												
Alternative Contact	No.					R	elations	hip					
Date of Birth:						E	thnicity	:			Ge	nder:	
GP Surgery:													•
Country Of Birth:					Interpreter Ne	eded?	YES			Language	:		
					Refe	rrer [Details						
Referrer name:							Ema	ail:					
Pharmacy:							Tel i	no:					
Job Role:							Fax	No:					
					Current	Subs	tance l	Jse	-				
Alcohol C	rack		Amp	hetan	nines 🗌	Det	ails:						
Opiates 🗌 Co	ocaine		Cann	abis									
					Curre	nt Tre	eatmen	t					
Is client currently in receipt of OST:	YE	s 🗌	NO		UNKNOWN			at OST is at what		rescribed			
How long have they OST in this treatment			pt of										
Drug and Alcohol Tr	reatmer	nt Prov	ider:										
Keyworker:								Conta	ct No:				
Test Results													
Date of Test:						Posit	ive RNA	Test		IU/N	ЛL		
Have you been	YES [NO 🗌				lt of HI\	/					
tested for HIV? Have you been							lt of HA	V					
tested for HAV?	YES		NO 🗌			Test:							
Have you been tested for HBV?	YES []	NO 🗌			Resu Test:	lt of HB	v					
					Additio	nal In	format	ion					
Any relevant medic			-	-	-								
* UID = Patient Uni	que Id	entific	ation -	each	pharmacy w	ill be j	provide	d with	a UID le	tter and	numb	er	

Consent obtained for referral and the sharing of the patient information outlined above

Please attach any available results to this referral and send to the hepatology team at relevant hospital